Besides gefitinib, which is a first-generation receptor tyrosine kinase inhibitor (RTKI), there are several other FDA-approved EGFR-targeting drugs for treatment of different types of cancer whose antiviral potential still has to be elucidated. Here, EGFR is linked to cancer.